Trial reportEuropean journal of nuclear medicine and molecular imaging2009
The effects of d-amphetamine on extrastriatal dopamine D2/D3 receptors: a randomized, double-blind, placebo-controlled PET study with [11C]FLB 457 in healthy subjects.
Trial report in European journal of nuclear medicine and molecular imaging, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 36 citations in OpenAlex.
- Cortical Dopamine Transmission as Measured with the [11C]FLB 457 - Amphetamine PET Imaging Paradigm Is Not Influenced by COMT Genotype.PloS one · 2016Trial
- A positron emission tomography study of nigro-striatal dopaminergic mechanisms underlying attention: implications for ADHD and its treatment.Brain : a journal of neurology · 2013Trial
- Changes in dopamine D2-receptor binding are associated to symptom reduction after psychotherapy in social anxiety disorder.Translational psychiatry · 2012Trial
- The chemical tools for imaging dopamine release.Cell chemical biology · 2021Review
- Failure to detect amphetamine-induced dopamine release in the cortex with [Synapse (New York, N.Y.) · 2018Article
- Serotonin concentration enhancers at clinically relevant doses reduce [Translational psychiatry · 2018Article
- The pharmacology of amphetamine and methylphenidate: Relevance to the neurobiology of attention-deficit/hyperactivity disorder and other psychiatric comorbidities.Neuroscience and biobehavioral reviews · 2018Review
- Application of cross-species PET imaging to assess neurotransmitter release in brain.Psychopharmacology · 2015Review
- Imaging dopamine transmission in the frontal cortex: a simultaneous microdialysis and [11C]FLB 457 PET study.Molecular psychiatry · 2014Article
- Neurofunctional imaging of β-cell dynamics.Diabetes, obesity & metabolism · 2012Review
- Dopaminergic neurotransmission in the human brain: new lessons from perturbation and imaging.The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry · 2012Review
- Evaluation of dopamine D₂/₃ specific binding in the cerebellum for the positron emission tomography radiotracer [¹¹C]FLB 457: implications for measuring cortical dopamine release.Synapse (New York, N.Y.) · 2011Article
- Article
- Striatal and extrastriatal dopamine release measured with PET and [(18)F] fallypride.Synapse (New York, N.Y.) · 2010Article
- COMT Val158Met genotype does not alter cortical or striatal dopamine D2 receptor availability in vivo.Molecular imaging and biology · 2010Article
- Impact of D2 receptor internalization on binding affinity of neuroimaging radiotracers.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2010Article
- Testing for radioligand sensitivity to endogenous neurotransmitter release.European journal of nuclear medicine and molecular imaging · 2009Review
Corrections and comments
- Commented on by
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe dopamine D(2)/D(3) receptor ligand [(11)C]FLB 457 and PET enable quantification of low-density extrastriatal D(2)/D(3) receptors, but it is uncertain whether [(11)C]FLB 457 can be used for measuring extrastriatal dopamine release.
methodsWe studied the effects of d-amphetamine (0.3 mg/kg i.v.) on extrastriatal [(11)C]FLB 457 binding potential (BP(ND)) in a randomized, double-blind, placebo-controlled study including 24 healthy volunteers.
resultsThe effects of d-amphetamine on [(11)C]FLB 457 BP(ND) and distribution volume (V(T)) in the frontal cortex were not different from those of placebo. Small decreases in [(11)C]FLB 457 BP(ND) were observed only in the posterior cingulate and hippocampus. The regional changes in [(11)C]FLB 457 BP(ND) did not correlate with d-amphetamine-induced changes in subjective ratings of euphoria.
conclusionThis placebo-controlled study showed that d-amphetamine does not induce marked changes in measures of extrastriatal dopamine D(2)/D(3) receptor binding. Our results indicate that [(11)C]FLB 457 PET is not a useful method for measuring extrastriatal dopamine release in humans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.